Baxter International (BAX) | Financial Analysis & Statements
Baxter International Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
3.0B
Gross Profit
577.0M
19.40%
Operating Income
-244.0M
-8.20%
Net Income
-1.1B
-37.93%
EPS (Diluted)
$-2.19
Balance Sheet Metrics
Total Assets
20.1B
Total Liabilities
14.0B
Shareholders Equity
6.1B
Debt to Equity
2.29
Cash Flow Metrics
Operating Cash Flow
-380.0M
Free Cash Flow
444.0M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Baxter International Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 11.2B | 10.6B | 14.8B | 14.5B | 12.1B |
| Cost of Goods Sold | 7.9B | 6.7B | 9.8B | 9.4B | 7.4B |
| Gross Profit | 3.4B | 4.0B | 5.0B | 5.1B | 4.7B |
| Gross Margin % | 30.1% | 37.5% | 33.6% | 34.9% | 38.9% |
| Operating Expenses | |||||
| Research & Development | 518.0M | 590.0M | 667.0M | 602.0M | 531.0M |
| Selling, General & Administrative | 2.9B | 3.0B | 3.9B | 3.9B | 2.8B |
| Other Operating Expenses | -206.0M | -12.0M | - | - | - |
| Total Operating Expenses | 3.2B | 3.5B | 4.6B | 4.5B | 3.4B |
| Operating Income | 177.0M | 439.0M | 370.0M | 605.0M | 1.3B |
| Operating Margin % | 1.6% | 4.1% | 2.5% | 4.2% | 11.1% |
| Non-Operating Items | |||||
| Interest Income | 52.0M | 67.0M | 70.0M | 20.0M | 14.0M |
| Interest Expense | 290.0M | 408.0M | 512.0M | 415.0M | 207.0M |
| Other Non-Operating Income | -444.0M | -387.0M | -32.0M | -2.9B | -35.0M |
| Pre-tax Income | -505.0M | -289.0M | -103.0M | -2.6B | 1.1B |
| Income Tax | 395.0M | 37.0M | -34.0M | 4.0M | 83.0M |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 7.4% |
| Net Income | -957.0M | -638.0M | 2.7B | -2.4B | 1.3B |
| Net Margin % | -8.5% | -6.0% | 18.0% | -16.7% | 10.7% |
| Key Metrics | |||||
| EBITDA | 1.3B | 1.6B | 1.8B | 2.0B | 2.2B |
| EPS (Basic) | $-1.87 | $-1.27 | $5.25 | $-4.83 | $2.56 |
| EPS (Diluted) | $-1.87 | $-1.27 | $5.25 | $-4.83 | $2.53 |
| Basic Shares Outstanding | 513000000 | 510000000 | 506000000 | 504000000 | 502000000 |
| Diluted Shares Outstanding | 513000000 | 510000000 | 506000000 | 504000000 | 502000000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Baxter International Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 2.0B | 1.8B | 3.2B | 1.7B | 3.0B |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 1.9B | 1.7B | 2.7B | 2.6B | 2.6B |
| Inventory | 2.2B | 2.0B | 2.8B | 2.7B | 2.5B |
| Other Current Assets | 481.0M | 328.0M | 387.0M | 368.0M | 390.0M |
| Total Current Assets | 6.9B | 8.9B | 9.6B | 8.0B | 8.9B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 651.0M | 773.0M | 2.2B | 2.2B | 2.3B |
| Goodwill | 14.2B | 15.8B | 19.1B | 19.7B | 27.5B |
| Intangible Assets | 4.4B | 5.2B | 6.1B | 6.8B | 7.8B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 530.0M | 3.1B | 803.0M | 1.4B | 790.0M |
| Total Non-Current Assets | 13.2B | 16.9B | 18.7B | 20.3B | 24.6B |
| Total Assets | 20.1B | 25.8B | 28.3B | 28.3B | 33.5B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 999.0M | 968.0M | 1.2B | 1.1B | 1.2B |
| Short-term Debt | 84.0M | 2.8B | 2.8B | 1.5B | 639.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 127.0M | 1.0B | 110.0M | 161.0M | 97.0M |
| Total Current Liabilities | 3.0B | 6.5B | 6.5B | 4.7B | 4.2B |
| Non-Current Liabilities | |||||
| Long-term Debt | 9.7B | 10.6B | 11.6B | 15.7B | 17.7B |
| Deferred Tax Liabilities | 245.0M | 103.0M | 447.0M | 661.0M | 962.0M |
| Other Non-Current Liabilities | 192.0M | 132.0M | 178.0M | 217.0M | 287.0M |
| Total Non-Current Liabilities | 11.0B | 12.2B | 13.3B | 17.6B | 20.2B |
| Total Liabilities | 14.0B | 18.8B | 19.8B | 22.4B | 24.4B |
| Equity | |||||
| Common Stock | 683.0M | 683.0M | 683.0M | 683.0M | 683.0M |
| Retained Earnings | 13.7B | 14.9B | 16.1B | 14.0B | 17.1B |
| Treasury Stock | 10.9B | 11.1B | 11.2B | 11.4B | 11.5B |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 6.1B | 7.0B | 8.5B | 5.9B | 9.1B |
| Key Metrics | |||||
| Total Debt | 9.8B | 13.4B | 14.4B | 17.2B | 18.3B |
| Working Capital | 3.9B | 2.3B | 3.1B | 3.3B | 4.6B |
Balance Sheet Composition
Baxter International Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -900.0M | -326.0M | -69.0M | -2.7B | 1.0B |
| Depreciation & Amortization | 981.0M | 997.0M | 1.3B | 1.4B | 867.0M |
| Stock-Based Compensation | 117.0M | 114.0M | 133.0M | 153.0M | 146.0M |
| Working Capital Changes | -329.0M | -155.0M | -104.0M | -671.0M | -229.0M |
| Operating Cash Flow | -24.0M | 409.0M | 801.0M | -2.0B | 1.7B |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | - |
| Acquisitions | - | - | -6.0M | -263.0M | -10.5B |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | 0 | 34.0M | - | - | - |
| Investing Cash Flow | 58.0M | 50.0M | 20.0M | -252.0M | -10.5B |
| Financing Activities | |||||
| Share Repurchases | - | 0 | 0 | -32.0M | -600.0M |
| Dividends Paid | -348.0M | -590.0M | -586.0M | -573.0M | -530.0M |
| Debt Issuance | 2.0B | - | 0 | 0 | 11.9B |
| Debt Repayment | -5.8B | -2.7B | -2.6B | -954.0M | -2.8B |
| Financing Cash Flow | -4.5B | -1.2B | -3.6B | -1.6B | 8.1B |
| Free Cash Flow | 323.0M | 559.0M | 1.0B | 591.0M | 1.5B |
| Net Change in Cash | -4.5B | -693.0M | -2.8B | -3.9B | -662.0M |
Cash Flow Trend
Baxter International Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
86.31
Forward P/E
9.09
Price to Book
1.54
Price to Sales
0.85
PEG Ratio
0.73
Profitability Ratios
Profit Margin
-8.51%
Operating Margin
7.36%
Return on Equity
-13.71%
Return on Assets
2.83%
Financial Health
Current Ratio
2.31
Debt to Equity
160.28
Beta
0.62
Per Share Data
EPS (TTM)
$-1.75
Book Value per Share
$11.92
Revenue per Share
$21.92
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| BAX | 9.4B | 86.31 | 1.54 | -13.71% | -8.51% | 160.28 |
| Intuitive Surgical | 170.1B | 54.97 | 8.99 | 16.69% | 28.38% | 0.95 |
| Becton, Dickinson | 56.1B | 25.40 | 1.75 | 6.96% | 8.01% | 77.28 |
| AptarGroup | 8.0B | 21.10 | 2.99 | 15.10% | 10.40% | 57.10 |
| Repligen | 7.5B | 154.30 | 3.55 | 2.40% | 6.62% | 32.76 |
| Teleflex | 6.0B | 104.31 | 1.93 | 1.58% | -45.45% | 90.32 |
Financial data is updated regularly. All figures are in the company's reporting currency.






